| Title | Translational Cancer Research |
| Abbreviation | Transl. Cancer Res. |
| Publication Type | Journal |
| Subject Area, Categories, Scope | Radiology, Nuclear Medicine and Imaging (Q3); Cancer Research (Q4); Oncology (Q4) |
| h-index | 36 |
| Overall Rank/Ranking | 17002 |
| SCImago Journal Rank (SJR) | 0.247 |
| Impact Score | 0.81 |
| Publisher | AME Publishing Company |
| Country | China |
| ISSN | 22196803, 2218676X |
| Best Quartile | Q3 |
| Coverage History | 2012-2022 |
Translational Cancer Research is a journal covering the technologies/fields/categories related to Radiology, Nuclear Medicine and Imaging (Q3); Cancer Research (Q4); Oncology (Q4). It is published by AME Publishing Company. The overall rank of Translational Cancer Research is 17002. According to SCImago Journal Rank (SJR), this journal is ranked 0.247. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 36. The best quartile for this journal is Q3.
The ISSN of Translational Cancer Research journal is 22196803, 2218676X. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Translational Cancer Research is cited by a total of 1377 articles during the last 3 years (Preceding 2022).
The Impact IF 2022 of Translational Cancer Research is 0.81, which is computed in 2023 as per its definition. Translational Cancer Research IF is increased by a factor of 0.34 and approximate percentage change is 72.34% when compared to preceding year 2021, which shows a rising trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2022 of Translational Cancer Research is 0.81. If the same upward trend persists, Impact IF may rise in 2023 as well.
| Year | Impact IF |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 0.81 |
| 2021 | 0.47 |
| 2020 | 0.70 |
| 2019 | 0.50 |
| 2018 | 0.38 |
| 2017 | 0.44 |
| 2016 | 1.12 |
| 2015 | 1.68 |
| 2014 | 1.83 |
Translational Cancer Research has an h-index of 36. It means 36 articles of this journal have more than 36 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Translational Cancer Research is 22196803, 2218676X. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Translational Cancer Research is 17002. According to SCImago Journal Rank (SJR), this journal is ranked 0.247. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 0.247 |
| 2021 | 0.185 |
| 2020 | 0.254 |
| 2019 | 0.312 |
| 2018 | 0.378 |
| 2017 | 0.435 |
| 2016 | 0.609 |
| 2015 | 0.637 |
| 2014 | 0.742 |
| Year | Ranking |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 17002 |
| 2021 | 19313 |
| 2020 | 16540 |
| 2019 | 14014 |
| 2018 | 11793 |
| 2017 | 10286 |
| 2016 | 7747 |
| 2015 | 7442 |
| 2014 | 6235 |
Translational Cancer Research is published by AME Publishing Company. It's publishing house is located in China. Coverage history of this journal is as following: 2012-2022. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Translational Cancer Research is Transl. Cancer Res.. This abbreviation ('Transl. Cancer Res.') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Radiology, Nuclear Medicine and Imaging (Q3); Cancer Research (Q4); Oncology (Q4), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Translational Cancer Research latest impact IF is 0.81. It's evaluated in the year 2022. The highest and the lowest impact IF or impact score of this journal are 1.83 (2014) and 0.38 (2018), respectively, in the last 9 years. Moreover, its average IS is 0.88 in the previous 9 years.
The Translational Cancer Research has an SJR (SCImago Journal Rank) of 0.247, according to the latest data. It is computed in the year 2023. In the past 9 years, this journal has recorded a range of SJR, with the highest being 0.742 in 2014 and the lowest being 0.185 in 2021. Furthermore, the average SJR of the Translational Cancer Research over the previous 9-year period stands at 0.88.
The latest h-index of the Translational Cancer Research is 36.
The Translational Cancer Research is published by the AME Publishing Company, with its country of publication being the China.
The Translational Cancer Research is currently ranked 17002 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 9 years, this journal has experienced varying rankings, reaching its highest position of 6235 in 2014 and its lowest position of 19313 in 2021.
The standard ISO4 abbreviation for the Translational Cancer Research is Transl. Cancer Res..
Translational Cancer Research is classified as a journal that the AME Publishing Company publishes.
The Translational Cancer Research encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The Translational Cancer Research is assigned the following International Standard Serial Numbers (ISSN): 22196803, 2218676X.
The best quartile for the Translational Cancer Research is Q3 (2022).
The Translational Cancer Research coverage history can be summarized as follows: 2012-2022.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| Journal of Competition Law and Economics | journal | 14815 | Oxford University Press | 29 | 0.72 |
| International Journal of Parallel, Emergent and Distributed Systems | journal | 15843 | Taylor and Francis Ltd. | 23 | 1.28 |
| Canadian Journal of Education | journal | 17961 | Canadian Society for the Study of Education (CSSE) | 41 | 0.39 |
| Abacus | journal | 8398 | Wiley-Blackwell Publishing Ltd | 49 | 2.52 |
| Journal of Sociolinguistics | journal | 5409 | Wiley-Blackwell Publishing Ltd | 61 | 1.96 |
| Korean Journal of Applied Microbiology and Biotechnology | journal | 22033 | Korean Society for Applied Microbiology | 0 | 0.00 |
| Indian Phytopathology | journal | 14222 | Springer Nature | 11 | 1.33 |
| Canadian Journal of Mathematics | journal | 3905 | Canadian Mathematical Society | 43 | 0.79 |
| Expert Review of Clinical Pharmacology | journal | 5241 | Taylor and Francis Ltd. | 53 | 4.10 |
| Transboundary and Emerging Diseases | journal | 4279 | Wiley-Blackwell Publishing Ltd | 78 | 4.95 |
| Year | Impact Score (IS) |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 0.81 |
| 2021 | 0.47 |
| 2020 | 0.70 |
| 2019 | 0.50 |
| 2018 | 0.38 |
| 2017 | 0.44 |
| 2016 | 1.12 |
| 2015 | 1.68 |
| 2014 | 1.83 |
